Cartesian Therapeutics (RNAC) Cash & Equivalents (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Cash & Equivalents for 12 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 99.06% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (down 99.06% YoY), while the FY2025 annual figure was $125.1 million, down 41.14% from the prior year.
• Cash & Equivalents eased to $1.7 million in Q1 2026 per RNAC's latest filing, from $125.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $219.2 million in Q3 2024 and bottomed at $1.7 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $105.8 million across 5 years, with a median of $112.0 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Equivalents surged 176.44% — and 2025, when it slumped 99.22%.
• Cartesian Therapeutics' Cash & Equivalents stood at $106.4 million in 2022, then retreated by 27.74% to $76.9 million in 2023, then soared by 176.44% to $212.6 million in 2024, then slumped by 41.14% to $125.1 million in 2025, then plunged by 98.64% to $1.7 million in 2026.
• Business Quant data shows RNAC's Cash & Equivalents at $1.7 million in Q1 2026, $125.1 million in Q4 2025, and $1.7 million in Q3 2025.